Kyprolis (carfilzomib) (approved): a covalent drug with high extrahepatic clearance via peptidase cleavage and epoxide hydrolysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Kyprolis (carfilzomib) (approved): a covalent drug with high extrahepatic clearance via peptidase cleavage and epoxide hydrolysis

Published:2023 Issue: Volume: Page:269-282
ISSN:
Container-title:Overcoming Obstacles in Drug Discovery and Development
language:
Short-container-title:

Author:

Wang Zhengping,Yang Jinfu,Kirk Christopher

Publisher

Elsevier

Reference67 articles.

1. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma;Siegel;Blood,2012

2. Approval summary for bortezomib for injection in the treatment of multiple myeloma;Bross;Clin. Cancer Res.,2004

3. The resurgence of covalent drugs;Singh;Nat. Rev. Drug Discov.,2011

4. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase;Pan;ChemMedChem,2007

5. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy;Honigberg;Proc. Natl. Acad. Sci.,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP